期刊
LANCET NEUROLOGY
卷 15, 期 2, 页码 219-230出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(15)00332-4
关键词
-
资金
- Accelerated Medicines Partnership [U01 AG046170]
- David Werber Family Trust
- Cure Alzheimer's Fund
- Veterans Affairs [I01RX000684]
- US National Institutes of Health
- National Multiple Sclerosis Society
- ALS Association
- Maryland Stem Cell Research Fund
- Brain & Behavior Research Foundation
- Stanley Foundation
- RUSK Foundation
- Maryland Stem Cell Research Funds
At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic treatments are modestly effective and off er only temporary benefit. Advances in induced pluripotent stem cell (iPSC) technology have the potential to enable development of so-called disease-in-a-dish personalised models to study disease mechanisms and reveal new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential drug candidates. Different cell types can also be produced for therapeutic use. In 2015, the US Food and Drug Administration granted investigational new drug approval for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells to treat Alzheimer's disease in the USA. Similar trials are either underway or being planned in Europe and Asia. Although safety and ethical concerns remain, we call for the acceleration of human stem cell-based translational research into the causes and potential treatments of Alzheimer's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据